Extended time action acylated insulin compounds
The presently described compounds relate to the treatment of Type I and/or Type II diabetes and/or hyperglycemia. More particularly, the described compounds relate to extended time action acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.
1 . A compound of Formula I:
wherein X is selected from the group consisting of -Lys-Gly-, -Lys-(2-[2-(2-aminoethoxy)ethoxy]acetic acid)-, and -εLys-Gly-; or a pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 wherein X is -Lys-Gly-, or a pharmaceutically acceptable salt thereof.
3 . The compound of claim 1 wherein X is -Lys-(2-[2-(2-aminoethoxy)ethoxy]acetic acid)-, or a pharmaceutically acceptable salt thereof.
4 . The compound of claim 1 wherein X is -εLys-Gly-, or a pharmaceutically acceptable salt thereof.
5 . The compound of claim 1 that is
or a pharmaceutically acceptable salt thereof.
6 . The compound of claim 1 that is
or a pharmaceutically acceptable salt thereof.
7 . The compound of claim 1 that is
or a pharmaceutically acceptable salt thereof.
8 . A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
9 . A method of treating Type I and/or Type II diabetes in a patient comprising administering to a patient in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 8 .
10 . A method of treating hyperglycemia in a patient comprising administering to a patient in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 8 .
11 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, for use in therapy.
12 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, for use in the treatment of Type I and/or Type II diabetes.
13 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, for use in the treatment of hyperglycemia.